Condition: Leukemia · Acute Leukemia · Relapse Leukemia · Sponsor: Memorial Sloan Kettering Cancer Center
The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-r, NUP98-r, and NPM1-m acute leukemias.
This description comes directly from the study's public registry record.
Kuo-Kai Chin, MD · 646-608-4415 · Chin3@mskcc.org
Eytan Stein, MD · 646-608-3749 · SteinE@mskcc.org
Always discuss trial participation with your own doctor first.
| City of Hope Cancer Center (Data collection only) | Duarte, California, United States | Not Yet Recruiting |
| Memorial Sloan Kettering at Basking Ridge (All Protocol Activities) | Basking Ridge, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Monmouth (All Protocol Activities) | Middletown, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Bergen (All Protocol Activities) | Montvale, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities) | Commack, New York, United States | Recruiting |
| Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Nassau (All Protocol Activities) | Rockville Centre, New York, United States | Recruiting |
| University of North Carolina (Data Collection Only) | Chapel Hill, North Carolina, United States | Not Yet Recruiting |
| MD Anderson Cancer Center (Data Collection Only) | Houston, Texas, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07356154